Tagged Articles

AndroGel 179 articles

AndroGel’s label did not warn of cardiovascular risks

AbbVie Inc., never mentioned on the safety label of its testosterone replacement therapy AndroGel that users were at an increased risk of cardiovascular events, including blood clots like those that lodged in the lungs of a man suing the drug company, his attorneys said in opening arguments to an Illinois federal jury this week. Robert Nolte’s case is the third bellwether trial AbbVie has faced in a multidistrict litigation of consisting of about 7,500 cases of men alleging testosterone treatment makers did not adequately warn doctors or consumers that their products were linked to an increased risk of heart attacks, ... Read More

Third AndroGel side effects trial begins this week

AbbVie Inc. faces its third bellwether trial this week over claims that testosterone replacement therapy AndroGel caused serious cardiovascular injuries. The case is one of more than 7,500 pending in a multidistrict litigation in Illinois federal court that names several testosterone treatment manufacturers and various testosterone products. The latest trial involves the case of Robert Nolte and his wife Genienne, who sued AbbVie in 2014 after Robert suffered a pulmonary embolism, a life threatening condition caused when blood clots travel to the lungs. He claims AbbVie did not adequately warn that use of AndroGel carried cardiovascular risks, including heart attacks, ... Read More

Several testosterone side effects trials scheduled through 2019

Three trials involving testosterone side effects have taken place in 2017 and another 10 or 11 cases are scheduled to be tried through 2019, due to U.S. District Judge Matthew Kennelly’s interest in ensuring all plaintiffs and defendants have the benefit of timely bellwethers. The multidistrict litigation is consolidated in the U.S. District Court for the Northern District of Illinois and names a handful of testosterone manufacturers including AbbVie Inc., Eli Lilly & Co., and Auxilium Pharmaceuticals Inc. There are also state cases by Illinois residents against AbbVie. The Cook County judge is coordinating with Judge Kennelly on those cases. ... Read More

Judge orders new trial in testosterone MDL, overturns verdict

The $150 million verdict awarded in the first bellwether trial alleging AbbVie Inc., fraudulently misrepresented its testosterone replacement therapy AndroGel was tossed out by an Illinois federal judge last week and a new trial ordered. U.S. District Judge Matthew Kennelly said the jury’s verdict was “internally inconsistent” because jurors awarded punitive damages based on the misrepresentation claim, but did not award compensatory damages because they did not find the drug company liable for the plaintiff’s injury. “Of course, it would violate the precepts of logic to assert simultaneously that a party has been damaged and not been damaged,” Judge Kennelly ... Read More

Eli Lilly announces settlement agreement of testosterone side effects cases

A month before facing its first bellwether trial in a multidistrict litigation involving testosterone side effects, Eli Lilly& Co., announced it had reached a global settlement in all cases filed against it. The drug company faced claims that the company failed to warn that its testosterone replacement therapy Axiron could cause potentially deadly heart attacks, strokes and blood clots. The pharmaceutical company told U.S. District Judge Matthew Kennelly that it had entered into a memorandum of understanding. As a result, Judge Kennelly canceled two upcoming trial dates – in January and March – involving Axiron. The trials involved the case ... Read More

Endo faces more testosterone side effects trials

Endo Pharmaceutical may have gotten a pass on the latest testosterone side effects trial, but its problems are far from resolved. The drug company faces nearly 1,300 lawsuits involving its testosterone replacement therapy Testim, as well as other testosterone products it markets, in state and federal courts. Endo faced the third trial in a class action lawsuit against several manufacturers of testosterone treatments over claims that the drugs caused cardiovascular side effects including heart attacks, strokes, blood clots and death. The first two trials were waged against AbbVie Inc., maker of the blockbuster testosterone treatment AndroGel, and resulted in verdicts ... Read More

Auxilium escapes verdict in testosterone side effects trial

Auxilium Pharmaceuticals Inc., maker of the testosterone replacement therapy Testim, escaped a verdict in the first bellwether trial blaming Testim for a man’s heart attack. This marks the first victory in multidistrict litigation (MDL) over testosterone side effects that names several testosterone manufacturers. The first two bellwether trials were against AbbVie Inc., makers of AndroGel, and resulted in combined $290 million in verdicts. The seven-day trial focused on the case of Steve Holtsclaw, who claimed he was prescribed Testim after complaining to his doctor about chronic fatigue. Months after treatment, Holtsclaw suffered a heart attack. He since learned that studies ... Read More

Testim benefits not worth the heart attack, patient says

Steve Holtsclaw’s heart attack in 2014 weighs on his mind daily. He’s more emotional now, and constantly wonders, “How much longer have I got?” the 62-year-old man told an Illinois federal jury during the first bellwether trial in a multidistrict litigation (MDL) involving cardiovascular risks with Auxilium Pharmaceuticals Inc.’s testosterone replacement therapy Testim. Holtsclaw was prescribed Testim in 2013 after complaining to his doctor about chronic fatigue. A blood test showed his testosterone levels were low. Months later, Holtsclaw suffered a heart attack. He received two stents and was put on several medications to help prevent a second heart attack. ... Read More

Opening arguments begin in latest testosterone trial

The Food and Drug Administration (FDA) repeatedly rejected Auxilium Pharmaceuticals Inc.’s requests to expand the indication of its testosterone replacement therapy Testim to include age-related drops in testosterone, yet the drug company continued to market its product for age-related symptoms, attorneys for Steve Holtsclaw said during opening arguments. As a result, Holtsclaw trusted the product was safe, but realized the error of his ways when he suffered a heart attack seven months after starting the hormone therapy. Holtsclaw’s lawsuit is the first bellwether to reach trial against Auxilium in a multidistrict litigation that names numerous manufacturers of testosterone treatments. Two ... Read More

Auxilium to take hot seat in latest testosterone side effects trial

Weeks after two juries handed down multi-million verdicts to two men who claimed that AbbVie Inc., did not adequately warn of cardiovascular risks with its testosterone replacement therapy AndroGel, drug maker Auxilium Pharmaceuticals LLC will take the hot seat in court over allegations that its testosterone treatment Testim caused a man to suffer a heart attack. Steve Holtsclaw is one of thousands of men alleging manufacturers of testosterone replacement therapy misrepresented what their products were safe and effective to treat while failing to warn that the drugs increased the risk of heart attacks, strokes and blood clots. Holtsclaw claimed he ... Read More